Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Active Lupus Nephritis
NCT07229742Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing SHR-2173 Group with Placebo Group (2 arms). Primary endpoint: Ratio of 24-hour urine protein-creatinine ratio to baseline at 24 weeks. Started Nov 2025; status: recruiting.
02
Drugs
SHR-2173
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07229742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229742.